



An Introduction to the Swedish Center for Better Medicine Use

Staffan Castensson and Anders Ekedahl
Department of Medicine Use

2010 International Symposium on Safe Medicine
October 10 – 12, 2010

Disclosure

- The presenters DO NOT have an interest in selling a technology, program, product, and/or service to CME/CE professionals.
- Staffan Castensson and Anders Ekedahl have nothing to disclose with regard to commercial relationships.
- The content of this presentation does not relate to any product of a commercial interest. Therefore, there are no relevant financial relationships to disclose.

Disposition

- A small flash-back
- Swedish health care; key figures
- Establishment of a Swedish Center for Better Medicine Use
- Deficiencies in prescribing and patient information on the prescribed treatment - a reason for medication errors, lack of adherence and drug waste

Last year's symposium



Pharmaceutical waste stream measurements as an avenue to sustainable pharmacy

Staffan Castensson, Ph.D., Assoc. Prof.

2009 International Symposium on Pharmaceuticals in the Home and Environment
October 18-20, 2009

© Apoteket AB v. 1.01 2010-09-28 Sida 2
Staffan Castensson/Research & Development

Sustainable pharmacy

$$\text{Rational drug use grade} \approx \frac{\text{Healthcare footprint}}{\text{Ecological footprint}}$$

$$\text{Rational drug use grade} \approx \frac{1}{\text{Waste level}}$$

Ministry of Health and Social Affairs

- **Memorandum 21st of December 2009**
 - Better medicine use in a de-regulated pharmacy market
- **Some specific needs to be focused**
 - Adverse drug reactions
 - Interactions
 - Prescribing errors
 - Non adherence

Mission given to the Medical Products Agency (MPA)

- To investigate and follow-up the de-regulated pharmacy market and work for co-ordination and co-work
- Establish a Center for Better Medicine Use or other similar functional structure
- Establish a Council for Better Medicine Use

The role and competence of MPA

- **the expert authority on pharmaceuticals**
 - Gives market authorization on new products
 - Performs benefit/risk judgements
 - Performs pharmacovigilance
 - Control and supervision of pharmaceutical products
 - Informs other authorities and individuals
 - Gives independent information to the public

A Swedish National Drug Strategy

- **Vision**
- Rational medicine use for the benefit of the patient and the society
- **Long term goal**
 1. World class medical results and patient safety
 2. Health care equality
 3. Cost effective medicine use
 4. Good innovative climate for products and services
 5. Minimal negative environmental impact

Drug related costs in Sweden

Drug products costs SEK 35 billions per year (USD 5 billions)

- 12% of total public health care costs

Drug related health care loss is supposed to be SEK 10 billions per year (USD 1.4 billions)

- Hospitalization and loss in production
- 20-30% related to prescribing errors or wrong administration
- 50% related to non-adherence